VOR BIOPHARMA INC (VOR)
Health Care · biotechnology · NASDAQ
Vor Biopharma is a clinical-stage biotech firm engineering hematopoietic stem cells to create safer and more effective treatment regimens for patients with blood cancers.
What VOR BIOPHARMA INC does
Vor Biopharma is a clinical-stage cell and genome engineering company focused on developing therapies for hematological malignancies. The company utilizes its proprietary platform to engineer hematopoietic stem cells to be resistant to targeted therapies, allowing for more precise treatment of blood cancers.
Themes: cell therapy, gene editing, hematology / oncology
Fundamentals
- Price$19.13 as of 2026-10-08 close
- Market cap$1.1B as of 2026-08-06 (share count; price 2026-10-08)
- 1-year return-42.7% 2025-10-08 close $33.40 → 2026-10-08 close $19.13
- P/En/a negative earnings
- Debt / equity0.00 as of 2026-09-02
- Beta1.29 as of 2026-09-02
- Last reported earnings2026-01-12 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How VOR compares in its sector
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How VOR BIOPHARMA INC looks technically
VOR BIOPHARMA INC (VOR) is trading 13.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 53 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 61.5% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 13.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +13.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.90 | $21.90 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.84 | $16.84 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 53 trading days ago — a "golden cross", a bullish long-term signal | 53 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($17.52 to $23.82) — its "stochastic" reading is 26 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 25.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.64 | $49.64 |
|---|---|---|
| From the 52-week high | it is 61.5% below its 52-week high (its highest price of the past year) | -61.5% |
| Above the 52-week low | it is 194.3% above its 52-week low (its lowest price of the past year) | +194.3% |
| Below the 52-week high | it is 61.5% below its highest point of the past year | 61.5% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 23 trading days ago | 23 sessions |
| All-time high | its highest closing price on record is $1272.40 (set on 2021-02-05) | $1272.40 |
| Given back of the 52-week move | over the past year its closes ranged ($6.86 to $39.26), and it has recovered roughly a third of its fall from last year’s high — 38% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.88 to $27.92. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 37.9% |
| From the all-time high | it is 98.5% below its all-time high | -98.5% |
| Nearest price level | it is trading 4.5% above a support level at $18.26 — a price it turned at twice since 2024-10-31, most recently on 2026-05-11. Since 2024-10-08 it has 5 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.5% |
| All-time low | its lowest closing price on record is $2.62 (set on 2025-05-09) | $2.62 |
| Above the all-time low | it is 630.2% above its all-time low | +630.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.27 between its high and its low — about 6.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.27 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $16.52 and $23.52 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $16.52 – $20.02 – $23.52 |
| Typical daily range (% of price) | its price moves about 6.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.6% |
| Stretch from the 200-day average | it is trading 1.8 daily ranges above its 200-day average price (13.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.27× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Open gap | it gapped 2.5% below the previous close 21 sessions ago and has not traded back through the level it left behind at 25.1 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.5% |
| Gap filled | a 2.6% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.48% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 24.8 percentage points (the stock lost 23.8% while the market gained 1.0%) | -24.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.6 percentage points (the stock lost 5.8% while the market gained 3.8%) | -9.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 0.1 percentage points (the stock gained 17.6% while the market gained 17.5%) | +0.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 57.7 percentage points (the stock lost 42.7% while the market gained 15.0%) | -57.7% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 16.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -1.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $17.12 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +11.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $21.47 — a volume-weighted average of daily closes over 42 sessions, not a true tick-by-tick VWAP. | -10.9% |
Price levels it has turned at before
VOR last closed at $19.13 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $18.26 | Support | 4.5% below the last close | turned there twice · 2024-10-31 to 2026-05-11 |
| $16.81 | Support | 12.1% below the last close | turned there five times · 2025-04-23 to 2026-07-17 |
| $21.98 | Resistance | 14.9% above the last close | turned there five times · 2024-12-09 to 2026-09-01 |
| $14.82 | Support | 22.5% below the last close | turned there twice · 2025-04-14 to 2026-02-10 |
| $24.43 | Resistance | 27.7% above the last close | turned there three times · 2025-01-23 to 2026-08-19 |
| $31.60 | Resistance | 65.2% above the last close | turned there twice · 2025-01-24 to 2025-02-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$39.00 range $27.00 – $50.00; median $40.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VOR
- Consensus EPS estimate-$0.72 next reporting period, as of 2026-10-07
- Estimate change, 30 days-$0.01702 from -$0.703, on 2026-09-02, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial development risk and potential failure to achieve desired efficacy or safety endpoints","High reliance on third-party contract manufacturing organizations and intellectual property licenses","Significant capital requirements and potential need for additional dilutive funding to support ongoing operations"]
What changed in the latest 10-Q
AI-assisted comparison of VOR's 10-Q filed 2026-05-13 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Annual Report instead of 2024 Annual Report (newer filing dated 2026-05-13)
- Statement that telitacicept has two BLAs 'filed and pending' in China for SjD and IgAN (newer filing)
- Statement that topline data from gMG Phase 3 trial is anticipated in first half of 2027 (newer filing)
- Reference to 48-week data from Part B of Phase 3 gMG trial presented at AANEM Annual Meeting in October 2025 (newer filing)
- New paragraph describing Phase 3 clinical trial for SjD with first patient dosed in March 2026 and expected recruitment of approximately 250 adults (newer filing)
- Reference to 48-week data including Stage A and B from Phase 3 SjD trial presented at ACR Annual Meeting in October 2025 (newer filing)
- Net loss of $219.6 million for three months ended March 31, 2026 and $32.5 million for three months ended March 31, 2025 (newer filing)
- Accumulated deficit of $1,372.6 million as of March 31, 2026 (newer filing)
- Cash, cash equivalents and marketable securities of $491.5 million as of March 31, 2026 (newer filing)
- Statement that cash is expected to fund operations into early 2029 (newer filing)
- Section on Critical Accounting Estimates with statement that there have been no changes from 2025 Annual Report (newer filing)
- Removed:
- Detailed description of telitacicept mechanism of action (TACI receptor, Fc domain, BLyS/BAFF, APRIL targeting) present in older filing removed from newer filing
- Statement that RemeGen 'has also filed' BLAs in China (older filing language) replaced with 'has two BLAs filed and pending' (newer filing)
- Detailed gMG Phase 3 trial results data (MG-ADL and QMG mean changes, percentage improvements, safety profile details) present in older filing not included in newer filing
- Reference to 'broader development plan' and exploration of additional autoantibody-driven diseases (older filing) removed from newer filing
- Detailed SjD Phase 3 trial results data (ESSDAI scores, ESSPRI scores, MFI-20 fatigue data, percentages at various timepoints) present in older filing not included in newer filing
- Restructuring Plan section describing May 5, 2025 board approval, wind down of existing operations, workforce reduction of 154 employees and restructuring costs of $29.7 million (older filing) removed from newer filing
- Net loss of $812.7 million for three months ended September 30, 2025, $2,418.8 million for nine months ended September 30, 2025, and $116.9 million for year ended December 31, 2024 (older filing) replaced with different figures for different periods (newer filing)
- Accumulated deficit of $2,875.8 million as of September 30, 2025 (older filing) replaced with $1,372.6 million as of March 31, 2026 (newer filing)
- Cash balance of $170.5 million as of September 30, 2025 and reference to net proceeds of $49.8 million (older filing) replaced with $491.5 million as of March 31, 2026 (newer filing)
- Reworded:
- Changed from 'are assuming responsibility' to 'have assumed responsibility' for gMG Phase 3 trial (past tense in newer filing)
- Removed reference to 'open-label treatment period (Part B)' and replaced with 'Part B' in gMG trial data description (newer filing)
- Changed 'Sjögren's disease' abbreviation from 'SD' (older filing) to 'SjD' (newer filing)
- Removed sentence about 'no approved disease-modifying systemic therapies for Sjögren's disease' (older filing statement not in newer filing)
- Notes:
- The newer filing (2026-05-13) covers the period ended March 31, 2026, while the older filing (2025-11-13) covers the period ended September 30, 2025, making direct financial comparison between different quarters
- The section appears truncated in the newer filing text (ends mid-sentence: 'A significant portion of our research and development costs have be'), limiting complete assessment of all changes in that section
- The older filing appears to be incomplete or truncated (ends mid-sentence regarding net proceeds), affecting full comparison of certain sections
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($4207) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 7 sells ($25M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-16. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VOR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VOR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 11,370,431
- Reported value $209,329,636
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about VOR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
VOR had 7,904,520 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
VOR had 13.4% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.12 days to cover at the same settlement.
- Reported short interest (shares) 7,904,520
- Short interest (% of shares outstanding) 13.4%
- Prior settlement (shares) 7,666,676
- Reported change 3.1%
- Days to cover (reported) 11.12
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- CRISPR Therapeutics (CRSP)
- Intellia Therapeutics (NTLA)
- Beam Therapeutics (BEAM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VOR vs…
VOR BIOPHARMA INC is found in…
Frequently asked questions
What does VOR BIOPHARMA INC (VOR) do?
Vor Biopharma is a clinical-stage cell and genome engineering company focused on developing therapies for hematological malignancies. The company utilizes its proprietary platform to engineer hematopoietic stem cells to be resistant to targeted therapies, allowing for more precise treatment of blood cancers.
What sector is VOR BIOPHARMA INC (VOR) in?
VOR BIOPHARMA INC (VOR) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are VOR BIOPHARMA INC's (VOR) competitors?
Notable peers of VOR BIOPHARMA INC (VOR) include Gilead Sciences, Novartis, Bristol Myers Squibb, CRISPR Therapeutics and Intellia Therapeutics. This peer set is informational only — not financial advice.
Is VOR BIOPHARMA INC (VOR) overbought or oversold right now?
VOR BIOPHARMA INC (VOR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VOR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.